A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fi...
Combination arms to treat patients in first-line setting, providing valuable insights on future development potential for this patient population Phase ...
Hansa Biopharma, "Hansa", a pioneer in enzyme technology for rare immunological conditions, announced high-level results from NICE-01, the first-in-h...
Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for dis...
-Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, announced an extension ...
Thailand Hub of Talents in Cancer Immunotherapy (TTCI), funded by the National Research Council of Thailand (NRCT), has been recently launched by ...
“This reanalysis indicates that patients undergoing molecular testing at laboratories using CAP PT can continue to be confident that their test resul...
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein DLL3 was discovered using OBT&rsq...
In a powerful display of solidarity with breast cancer warriors and patients, Avantor, a leading global supplier of products, services, and solutions for l...
--Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150 million under management, announc...
MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the Universit...
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluatin...
Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more tha...
© 2024 Biopharma Boardroom. All Rights Reserved.
